CONSHOHOCKEN, Pa., April 16, 2024 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to 7 new employees, in each case with a grant date of April 15, 2024, as equity inducement
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Nurix Therapeutics (NRIX – Research Report) and Madrigal Pharmaceuticals (MDGL – Research Report) with bullish sentiments.
Nurix Therapeutics (NRIX)
J.P. Morgan analyst Eric Joseph maintained a Buy rating on Nurix Therapeutics yesterday and set a price target of $30.00. The company’s shares closed last Tuesday at $17.48.
According to TipRanks.com, Joseph is a 3-star analyst with an average return of
Nurix Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $24.00, representing a 72.0% upside. In a report issued on March 25, Robert W. Baird also maintained a Buy rating on the stock with a $24.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Madrigal Pharmaceuticals (MDGL)
Citi analyst David Lebovitz maintained a Buy rating on Madrigal Pharmaceuticals yesterday and set a price target of $389.00. The company’s shares closed last Tuesday at $249.34.
According to TipRanks.com, Lebovitz is a 1-star analyst with an average return of
Currently, the analyst consensus on Madrigal Pharmaceuticals is a Strong Buy with an average price target of $391.14, representing a 55.6% upside. In a report issued on March 25, Piper Sandler also assigned a Buy rating to the stock with a $336.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on NRIX:
Madrigal Pharmaceuticals announced that Rezdiffra or resmetirom, is now available in the U.S. Rezdiffra is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic NASH
CONSHOHOCKEN, Pa., April 03, 2024 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to 30 new employees, in each case with a grant date of April, 1 2024, as equity
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Masimo (MASI – Research Report), ImmunityBio (IBRX – Research Report) and Madrigal Pharmaceuticals (MDGL – Research Report).
Masimo (MASI)
Piper Sandler analyst Jason Bednar maintained a Hold rating on Masimo today and set a price target of $117.00. The company’s shares closed last Friday at $134.93.
According to TipRanks.com, Bednar is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Masimo with a $135.50 average price target, implying a 1.9% upside from current levels. In a report released today, Needham also maintained a Hold rating on the stock.
See today’s best-performing stocks on TipRanks >>
ImmunityBio (IBRX)
In a report released today, Joseph Catanzaro from Piper Sandler maintained a Hold rating on ImmunityBio, with a price target of $5.00. The company’s shares closed last Friday at $6.07, close to its 52-week high of $6.93.
According to TipRanks.com, Catanzaro is a 5-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for ImmunityBio with a $5.00 average price target.
Madrigal Pharmaceuticals (MDGL)
In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Madrigal Pharmaceuticals, with a price target of $336.00. The company’s shares closed last Friday at $248.20.
According to TipRanks.com, Rahimi is a 4-star analyst with an average return of
Madrigal Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $391.14, representing a 51.3% upside. In a report issued on March 14, Canaccord Genuity also maintained a Buy rating on the stock with a $377.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MASI: